Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 1, 2008, Pages 15-20

  Ogata, Kenji ^a,b   Takamura, Norito ^a   Tokunaga, Jin ^a   Kawai, Keiichi ^c   Arimori, Kazuhiko ^d   Higuchi, Shun ^b  

^a KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FLURBIPROFEN AXETIL; HUMAN SERUM ALBUMIN; LIPID EMULSION;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER PAIN; CONTROL GROUP; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG MIXTURE; FATTY ACID BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INJECTION; MALE; NONHUMAN; PROTEIN BINDING; RAT; STATISTICAL SIGNIFICANCE; ULTRAFILTRATION;

ALGORITHMS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EMULSIONS; FATTY ACIDS, NONESTERIFIED; FLURBIPROFEN; LINOLEIC ACID; LIPIDS; MALE; OLEIC ACID; PRODRUGS; PROTEIN BINDING; RATS; RATS, WISTAR; SERUM ALBUMIN; TIME FACTORS; ULTRAFILTRATION;

EID: 38349179783     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.1.0002     Document Type: Article

References (27)

1. Arimori, K., Nakano, M., Otagiri, M., Uekama, K. (1984) Effects of penicillins on binding of phenytoin to plasma proteins in vitro and in vivo. Biopharm. Drug. Dispos. 5: 219-227
2. Bhattacharya, A. A., Grune, T., Curry, S. (2000) Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J. Mol. Biol. 303: 721-732
3. Bjorkman, R., Ullman, A., Hedner, J. (1993) Morphine-sparing effect of diclofenac in cancer pain. Eur. J. Clin. Pharmacol. 44: 1-5
4. Brown, J. E., Kitchell, B. B., Bjornsson, T. D., Shand, D. G. (1981) The artifactual nature of heparin-induced drug protein-binding alterations. Clin. Pharmacol. Ther. 30: 636-643
5. Carter, D. C., Ho, J. X. (1994) Structure of serum albumin. Adv. Protein Chem. 45: 153-203
6. Cherny, N. I. (2000) The management of cancer pain. CA Cancer. J. Clin. 50: 70-116
7. Chuang, V. T., Otagiri, M. (2002) How do fatty acids cause allosteric binding of drugs to human serum albumin? Pharm. Res. 19: 1458-1464
8. Dasgupta, A. (2002) Clinical utility of free drug monitoring. Clin. Chem. Lab. Med. 40: 986-993
9. Dionigi, P., Dionigi, R., Prati, U., Pavesi, F., Jemos, V., Nazari, S. (1985) Effect of Intralipid on some immunological parameters and leukocyte functions in patients with esophageal and gastric cancer. Clin. Nutr. 4: 229-234
10. Doumas, B. T., Watson, W. A., Biggs, H. G. (1971) Albumin standards and the measurement of serum albumin with bromcresol green. Clin. Chim. Acta. 31: 87-96
11. Joishy, S. K., Walsh, D. (1998) The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome. J. Pain Symptom Manage. 16: 334-339
12. Menke, G., Worner, W., Kratzer, W., Rietbrock, N. (1989) Kinetics of drug binding to human serum albumin: allosteric and competitive inhibition at the benzodiazepine binding site by free fatty acids of various chain lengths. Naunyn Schmiedebergs Arch. Pharmacol. 339: 42-47
13. Naranjo, C. A., Sellers, E. M., Khouw, V., Alexander, P., Fan, T., Shaw, J. (1980) Variability in heparin effect on serum drug binding. Clin. Pharmacol. Ther. 28: 545-550
14. Pace, V. (1995) Use of nonsteroidal anti-inflammatory drugs in cancer. Palliat. Med. 9: 273-286
15. Petitpas, I., Grune, T., Bhattacharya, A. A., Curry, S. (2001) Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J. Mol. Biol. 314: 955-960
16. Reaven, G. M., Hollenbeck, C., Jeng, C. Y., Wu, M. S., Chen, Y. D. (1988) Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37: 1020-1024
17. Shimizu, S., Inoue, K., Tani, Y., Yamada, H. (1979) Enzymatic microdetermination of serum free fatty acids. Anal. Biochem. 98: 341-345
18. Sudlow, G., Birkett, D. J., Wade, D. N. (1976) Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol. 12: 1052-1061
19. Takamura, N., Maruyama, T., Chosa, E., Kawai, K., Tsutsumi, Y., Uryu, Y., Yamasaki, K., Deguchi, T., Otagiri, M. (2005) Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome. Drug. Metab. Dispos. 33: 596-602
20. Takamura, N., Tokunaga, J., Chosa, E., Kawai, K., Fujita, K., Arimori, K. (2007) Pharmaceutical skill using displacement of protein binding for pharmacists. Yakugaku Zasshi. 127: 1805-1811
21. Takla, P. G., Schulman, S. G., Perrin, J. H. (1985) Measurement of flurbiprofen-human serum albumin interaction by fluorimetry. J. Pharm. Biomed. Anal. 3: 41-50
22. Wanwimolruk, S., Birkett, D. J., Brooks, P. M. (1983) Structural requirements for drug binding to site II on human serum albumin. Mol. Pharmacol. 24: 458-463
23. Watanabe, H., Tanase, S., Nakajou, K., Maruyama, T., Kragh-Hansen, U., Otagiri, M. (2000) Role of Arg-410 and Tyr-411 in human serum albumin for ligand binding and esterase-like activity. Biochem. J. 349: 813-819
24. Wolever, T. M., Bentum-Williams, A., Jenkins, D. J. (1995) Physiological modulation of plasma free fatty acid concentrations by diet. Metabolic implications in nondiabetic subjects. Diabetes Care 18: 962-970
25. World Health Organization (1986) Cancer pain relief. Geneva: WHO: 18-20
26. Zelcer, S., Kolesnikov, Y., Kovalyshyn, I., Pasternak, D. A., Pasternak, G. W. (2005) Selective potentiation of opioid analgesia by nonsteroidal anti-inflammatory drugs. Brain Res. 1040: 151-156
27. Zimmerman, C. L., Patel, I. H., Levy, R. H., Edwards, D., Nelson, S. D., Hutchinson, M. (1981) Protein binding of valproic acid in the presence of elevated free fatty acids in patient and normal human serum. Epilepsia 22: 11-17